Category Archives: Biotechnology

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares have been up over 80% on large volumes. PRAN closed yesterday at $2.48, gapped up to open at $2.95, reached an inter-day high of $4.58, and are now trading around $3.60 for an inter-day gain of over 45%. The nano-cap Australian-based biotech firm has, prior to todays action, an average daily trading volume of just over 59,000 but, by 10:30 AM EST, PRAN shares had already traded over 7.1 million times. A review of news services reveals that no news has been reported by the company or an analyst that could account for todays price action. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a clinical stage biotechnology firm that develops therapeutic medicines. Prana has developed PBT-2 for the treatment of Alzheimers disease. PBT-2 is currently in a Phase IIa clinical trial. Pranas PBT-2 is also being investigated for applications involving other therapeutic applications including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinsons disease, and other neurodegenerative diseases. When PRAN is adjusted for dilutive effects, the shares high came in early 2014 when PRAN was trading near $80/share. However, by the end of 2014, PRAN … Continue reading →

A Little Vertex Goes a Long Way For Biotechnology - Barron's Barron's Healthcare stocks are the second-best performing, behind just the information technology sector year-to-date. Healthcare stocks have gained 8.3%, while the ... and more » Read this article: A Little Vertex Goes a Long Way For Biotechnology - Barron's - Barron's … Continue reading →

With excellent mechanical and chemical stability, the Kromasil EternityXT materials offer first-rate separation power and loadability for purification from low to high pH. Kromasil EternityXT C8 and C18 materials can operate up to pH 12, making it possible to run basic compounds under extreme conditions to improve purification productivity and reduce costs. These products support discovery, development and production departmental goals in the purification of a low molecular weight pharmaceuticals, peptides and biotechnology products. The exceptional structure of Kromasil EternityXT C18 and C8 materials makes it possible to regenerate the material in-column, carrying out cleaning in place (CIP) even at 1 M NaOH, if so required. While this high concentration NaOH treatment is a standard in bio chromatography and until now only conceivable with polymer resins, Kromasil EternityXT materials open up the spectrum of purification options as its C8 and C18 materials resist up to 1 M NaOH. See the rest here: Purification of Pharmaceutical and Biotechnology Products with Kromasil EternityXT Stationary Phase - Labmate Online … Continue reading →

KARACHI: Pakistani agro-scientist should expedite their research activities in agro-biotechnology in order to create significant impact in enhancing agriculture production in the country. Talking to the Daily Times, agro-biotechnology experts and agriculturists on cotton, maize, corn and other crops said Pakistan should follow the developed world and developing nations like The Philippines and India who have already made significant economic progress by adopting the latest agri-technologies. Though Pakistan has been conducting regulatory field trials and research on ground for biotech cotton and corn but there was the need to exploit more avenues introduced in the modern agro-base technologies in the world. The concerned government departments and ministry should also allocate more funds in this sector in the upcoming annual budget, they opined. "Cotton has remained a vital cash crop and country needs above 16 million bales every crop season, as cotton related textile sector feeds a large number of direct and indirect employment besides textile export stands number one on five prime exporting sectors", President of Sindh Agriculture Forum, Shakeel Ahmad said. The positive impact of biotech crops around the world is evident in reducing pesticide usage, which is subsequently a positive for the environment, he added. Cotton, corn and … Continue reading →

What happened Cellect Biotechnology (NASDAQ:APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT. Image source: Getty Images. Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company. While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash andApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval. In addition, Bellicum Pharmaceuticals'adjunct T-cell therapy BPX-501 could … Continue reading →

Biotechnology Gets A Shot In the Arm Barron's The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far, suggesting that investors may be ... iShares Nasdaq Biotechnology (IBB) volatility low into Credit Suisse ...StreetInsider.com iShares NASDAQ Biotechnology Index (IBB) Rating Increased to ...BBNS all 5 news articles » Excerpt from: Biotechnology Gets A Shot In the Arm - Barron's … Continue reading →

Cellect Biotechnology Ltd (NASDAQ:APOP, TASE:APOP) shares shot up 74% in New York after it successfully performed the first stem cell transplant procedure on a cancer patient. It happened in the group's phase I/II clinical trial in a blood cancer patient. The stem cell firm's chief executive Dr Shai Yarkoni said: After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions. "It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world. Up to half of all stem cell transplant procedures, such as bone marrow transplants, result in life-threatening rejection disease, known as Graft-versus-Host-Disease (GvHD). But the firm's ApoGraft technology aims to stop all that. Now, the independent data and safety monitoring board (DSMB) has approved the enrolment of two further patients for the ApoGraft treatment to complete the first study cohort as planned. Shares shot up 74% to reach $10.9 each. Register here to be notified of future PROAC Company articles Continued here: First successful stem cell cancer transplant sees Cellect Biotechnology shares surge - Proactive Investors … Continue reading →

March 24, 2017 11:39 ET | Source: Research and Markets Dublin, March 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Agricultural Biotechnology: Emerging Technologies and Global Markets" report to their offering. The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals. These technologies and products are analyzed to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces. In-depth coverage of the agricultural biotechnology industry structure is provided, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016. 70 agricultural and biotechnology companies are profiled in this report. Key Topics Covered: 1: Introduction - Study Goals And Objectives - Reasons For Doing The Study - Intended Audience - Scope And Format - Methodology - Information Sources 2: Executive Summary … Continue reading →

Agricultural biotechnologies are being applied to an increasing extent in crops, livestock, forestry, fisheries and aquaculture and agro-industries, to alleviate hunger and poverty, assist in adaptation to climate change and maintain the natural resource base. They have not sufficiently benefited smallholder farmers and producers and consumers. More research and developmentof agricultural biotechnologies should be focused on the needs of smallholders. In order to produce food in a sustainable way for an additional 2 billion people by 2050, a business-as-usual approach will not be sufficient. This is especially true in the face of climate change and other forces threatening natural resources like biodiversity, land and water that are essential for food production and agriculture, including forestry and fisheries. To meet these challenges, science and the application of biotechnologies as well as conventional technologies will play a key role. FAO recognizes that when appropriately integrated with other technologies for the production of food, agricultural products and services, biotechnology can be of significant assistance in meeting the needs of an expanding and increasingly urbanized population. Regarding biotechnology, FAO assists its Member countries and their institutions by: Here is the original post: Biotechnology | FAO | Food and Agriculture Organization of ... … Continue reading →

Biotechnology is a popular trend that can be found in various aspects of our everyday lives. While it is true biotechnology is a very complicated concept to grasp, it is also one of the most promising technologies to be found today. Biotechnology will help our society address some of its greatest challenges moving forward. Below are some very common use cases for biotechnology most people will have come in contact with already. It is anything but surprising to learn biotechnology has made a big impact on the medical sector over the past few years. Biotechnology, or more specifically, bio-processing, is used to develop new pharmaceuticals which are often difficult to produce due to purity quality control requirements. Some of the more popular biotech pharmaceuticals include Remicade, Rituxan, Prevarn, and Avastin. Very few consumers give fabrics a second thought, other than to determine whether the material would rub against the skin. Interestingly enough, most fabrics are dyed through a fermentation vat process. Biochemicals are very common in the production of dyes, polyester, and nylon. It is evident there is some form of biotechnology involved in every piece of synthetic clothing we wear today. Even though biofuel is not as popular as … Continue reading →